Clinical Trial Details

Overview

Research Study Summary

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Purpose
This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints.
To Learn more

CW ID: 222914
Date Last Changed: February 3, 2017

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
45 and up
Overall Status
Recruiting
Lead Sponsor
DalCor Pharmaceuticals
Facility Type
N/A

Eligibility

Inclusion Criteria:
  • Subjects with the appropriate genetic background and recently hospitalized for ACS (between 4 and 12 weeks following the index event), will be enrolled in this trial.
  • AA genotype at variant gene as determined by Genotype Assay testing, conducted at a designated investigational testing site (ITS)
  • Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization
  • Prior to randomization, subject must have evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment to a target level of LDL-C <100 mg/dl (<2.6 mmol/L).

    Exclusion Criteria:

  • Females who are pregnant (negative pregnancy test required for all women of child-bearing potential at Visit 2, Day 0) or breast-feeding
  • Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not simultaneously using two effective contraceptive methods, and one of which being a barrier method (diaphragm, cervical cap, male condom, etc.)
  • New York Heart Association (NYHA) Class III or IV heart failure
  • Last known hemoglobin <10 g/dL
  • Index ACS event presumed due to uncontrolled hypertension
  • Contact

    Mirza Muratovic
    University of South Florida - USF Florida Cardiovascular Institute
    509 South Armenia Ave., 2nd Floor
    Tampa, FL 33609
    Phone: (727) 389-3512

    View Map

    DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.